Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5219_Библиотеки_им_академика_М_И_Перельмана.pdf
X
- •Foreword
- •Preface
- •Contents
- •Editors and Contributors
- •About the Editors
- •Contributors
- •1.1 Introduction
- •1.2 Conventional Methods
- •1.2.1 Microscopy
- •1.2.2 Culture
- •1.2.3 Germ Tube Test
- •1.2.5 Carbohydrate Assimilation Test
- •1.2.6 Nitrogen Assimilation Test
- •1.2.7 Carbohydrate Fermentation Test
- •1.2.8 Urease Test
- •1.2.9 Tween 80 Opacity Test
- •1.3 Nonculture-Based Conventional Methods
- •1.3.1 Serological Methods
- •1.3.1.2 ß-d-Glucan
- •1.3.1.3 C. albicans Germ Tube Antibody Assay (CAGTA)
- •1.4 Nucleic Acid-Based Detection
- •1.4.1 Polymerase Chain Reaction (PCR)
- •1.4.3 Peptide Nucleic Acid FISH (PNA-FISH)
- •1.4.4 PCR-Based Innovative Diagnosis
- •1.4.5 FilmArray System
- •1.4.6 Sepsis Flow Chip
- •1.4.7 ePlex System
- •1.4.8 The T2 Candida Assay
- •1.5 Rapid Identification Systems
- •1.5.1 Manual Rapid Identification System
- •1.5.1.1 The API System
- •1.5.1.2 The VITEK System
- •1.5.2 Automatic Rapid Identification System
- •1.5.2.1 MALDI-TOF MS
- •1.5.2.2 The MALDI Sepsityper IVD Kit
- •1.5.2.3 The BioFire FilmArray BCID2 Panel
- •1.5.2.4 The Accelerate Pheno BC Panel
- •1.6 Advanced Diagnostics
- •1.6.2 Biosensor-Based Tests
- •1.6.3 Next-Generation Sequencing (NGS)
- •1.7 Conclusion
- •References
- •2.1 Introduction
- •2.2.1.2 Echinocandins
- •First-Generation Echinocandin
- •Second-Generation Echinocandin
- •2.2.1.3 Other Cell Wall Inhibitors
- •2.2.2.1 Azoles
- •Imidazole
- •Triazole
- •Second-Generation Azole
- •Third-Generation Azole
- •2.2.2.2 Polyenes
- •Other Polyene Under Development
- •2.2.2.3 Allylamines
- •2.2.3 Flucytosine
- •2.3 Conclusion
- •References
- •3.1 Introduction
- •3.2.1 Control Diet
- •3.2.3 Toxification
- •3.2.4 Alternative Treatments
- •3.3.1 Prophylaxis
- •3.3.2 Preemptive Therapies
- •3.3.3 Empirical Therapies
- •3.4 Therapeutic Approach
- •3.4.1 Azoles
- •3.4.2 Echinocandins
- •3.4.3 Polyenes
- •References
- •4.1 Introduction
- •4.3 Eukarya Domain
- •4.4.1 Cryptococcus
- •4.4.2 Aspergillus
- •4.4.3 Mucorales
- •4.4.4 Candida
- •4.5.1 Candida albicans
- •4.5.2 Morphogenesis
- •4.5.3 Pathogenesis
- •4.5.4 Adherence
- •4.5.5 Morphological Switching
- •4.5.6 Invasion
- •4.6 Induced Endocytosis
- •4.7 Active Penetration
- •4.8.2 Biofilm Formation
- •4.8.4.1 Antifungals
- •4.8.4.2 Antifungal Resistance
- •References
- •5.1 Introduction
- •5.2.3.1 Serum
- •5.2.3.2 Low Nitrogen
- •5.2.3.5 Carbon Source
- •5.2.3.6 pH
- •5.2.3.7 N-acetylglucosamine (GlcNAc)
- •5.2.3.8 Quorum Sensing Molecule
- •5.5.5 Surface Colonization Factor1 (SCF1)
- •5.5.6 Other Putative Adhesins
- •5.6.1 Phospholipases
- •5.6.2 Proteinases
- •5.6.3 Hemolysins
- •5.6.4 Lipases
- •5.7 Secreted Cytolytic Peptide: Candidalysin
- •5.5.1 ALS Family
- •5.5.2 HWP Adhesin
- •5.5.3 HYR/IFF Family
- •5.5.4 EPA Family
- •5.9.2 Low Molecular Weight Hsp/Small Heat Shock Proteins
- •5.10.1 Amino Acid/Nitrogen Metabolism
- •5.10.1.1 Amino Acid Sensing Pathway
- •5.12.1.1 Glycolysis
- •5.12.1.2 Gluconeogenesis
- •5.12.1.3 Glyoxylate Cycle
- •5.12.1.4 Fatty Acid Oxidation
- •5.12.3.2 Iron Metabolism
- •5.12.3.3 Candida Iron Transport
- •5.12.3.4 Reductive System
- •5.12.3.5 Siderophore Uptake System
- •5.12.3.6 Haemoglobin-Iron Uptake System
- •5.13.2 Zinc Metabolism
- •References
- •6.1 Introduction
- •6.2 Morphological Switching
- •6.3 Phenotypic Switching
- •6.4 Biofilm Formation
- •6.5 Metabolic Flexibility
- •6.8.1 Hemolysin
- •6.8.2 Phospholipases
- •6.8.3 Proteinase
- •6.8.4 Candidalysin
- •6.12 Conclusion
- •References
- •7.1 Introduction
- •7.2.4 Polymorphism
- •7.2.5.1 Secreted Aspartyl Proteinases
- •7.2.5.2 Phospholipase
- •7.2.6 Calcineurin-Signalling Pathway
- •7.2.7 Ion Homeostasis
- •7.2.7.1 Iron
- •7.2.7.2 Copper
- •7.2.8.1 Capsule
- •7.2.8.2 Melanin
- •7.2.8.3 Heat Shock Proteins
- •7.3 Conclusions
- •References
- •8.1 Introduction
- •8.4.1 ATP-Binding Cassette (ABC) Transporters
- •8.4.2 Major Facilitator Superfamily (MFS) Transporter
- •8.5.1 Biofilm Architecture Among Candida Species
- •References
- •9.1 Introduction
- •References
- •10.1 Introduction
- •10.3 Biofilm
- •10.5 Adherence
- •10.6 Maturation
- •10.8 Dispersion
- •10.11 Animal Models
- •10.18 Photodynamic Therapy
- •References
- •11.1 Introduction
- •11.9 Concluding Remarks
- •References
- •12.1 Introduction
- •12.2 Epidemiology
- •12.3.1 Humoral Response
- •12.3.2 Cellular Immunity
- •12.4 Virulence Factors
- •12.6.1 Fluconazole
- •12.6.2 Polyenes
- •12.6.3 Echinocandins
- •12.7 Drug Resistance
- •12.8 Future Prospects
- •12.9 Conclusions
- •References
- •13.1 Introduction
- •13.4 Translation Research
- •13.4.1 Disease-Oriented Translational Research
- •13.4.2 Lab-Oriented Translational Research
- •13.4.3 Patient-Oriented Translational Research
- •13.5 Conclusion
- •References
- •14.1 Introduction
- •14.2.3 Cutaneous Aspergillosis
- •14.2.4 Ocular Aspergillosis
- •14.2.5 Aspergillus Endocarditis
- •14.2.6 Aspergillus Osteomyelitis
- •14.2.7 Sinus Aspergillosis
- •14.3.2 Histopathology
- •14.3.3 Serological
- •14.3.4 Breath Testing
- •14.3.5 Monoclonal Antibody (mAbs)-Mediated Methods
- •14.4.1 Conventional Therapeutics
- •14.4.1.1 Azoles
- •14.4.1.2 Polyenes
- •14.4.1.3 Echinocandins
- •14.4.1.4 Fluoropyrimidines
- •14.5 Nonconventional Therapeutics
- •14.5.1 Vaccine
- •14.5.2 Monoclonal Antibodies (mAbs)
- •14.5.3 Nanotechnology-Based Therapeutics
- •14.5.4 Immune Therapy
- •14.5.5 Combination Therapy
- •14.8 Conclusion
- •References
- •15: Aspergillus Therapeutics: Future Agents
- •15.1 Introduction
- •15.2.1 Fosmanogepix
- •15.2.2 Ibrexafungerp
- •15.2.3 Olorofim
- •15.2.4 Opelconazole
- •15.2.5 Rezafungin
- •15.2.6 MGCD290
- •15.2.7 Tetrazoles (VT-1129/VT-1161/VT-1598)
- •15.2.8 Nikkomycin Z
- •15.2.9 VL-2397
- •15.2.10 T-2307/ATI-2307
- •15.2.11 Encochleated Amphotericin-B
- •15.2.12 SUBA-Itraconazole
- •15.2.13 Immunotherapy
- •15.2.14 Drug Repurposing
- •References
- •16.1 Introduction
- •16.2 Antifungal Agents
- •16.2.1 Azoles
- •16.2.2 Posaconazole
- •16.2.3 Isavuconazole
- •16.2.4 SUBA—Itraconazole
- •16.2.5 Nanovoriconazole
- •16.2.6 Adverse Effects
- •16.3 Liposomal Amphotericin B (LAMB)
- •16.3.1 Echinocandins
- •16.4 Combination Antifungal Therapy
- •16.5 Therapeutic Drug Monitoring (TDM)
- •16.5.1 Azole-Resistant Aspergillus Spp.
- •16.6 Guideline Recommendations
- •16.10 Conclusion
- •References
- •17.1 Introduction
- •17.3 Potent Antifungal Molecules Under Investigations
- •References
- •19.2 Host–A. fumigatus Interactions
- •19.3.1 Hydrophobicity or Rodlet Layer
- •19.3.2 Conidiation
- •19.3.3 DHN Melanin
- •19.3.5 Siderophores
- •19.3.6 Biofilm Formation
- •19.4 Conclusion
- •References

18 A Comprehensive and Intricate Dynamics of Aspergillus: Implications…
445
For immunocompromised patients with invasive disease, itraconazole is considered a second-line treatment for aspergillosis. However, voriconazole is preferred
due to its superior intrinsic activity against Aspergillus species and better tolerance
in both intravenous and oral forms (Moritomo et al. 2013). The use of itraconazole
is limited due to its variable bioavailability and potential toxicities, with insufcient
data supporting the use of the intravenous formulation. In a signicant nonrandomized trial, only 39% of IPA patients exhibited a full or partial response to itraconazole, while 26% showed no improvement. Particularly, poor outcomes were
observed in patients with AIDS and those undergoing allogeneic bone-marrow
transplantation. However, itraconazole remains a valuable alternative in less invasive diseases and for allergic syndromes, where it can be benecial (Denning
etal. 1994).
Creating antimicrobial drugs to cure bacterial and fungal infections is a difcult
task. According to Roemer and Boone (2013), the discovery of novel chemical scaffolds by bacteria and fungi during the golden age of antibiotics, which lasted from
the years 1940 to 1970, revolutionized modern medicine. The only novel class of
antifungal medications to reach clinical use in the past 30years, however, is echinocandins (Pagadala et al. 2017; Shapiro etal. 2011). The widespread, worldwide
evolution of resistance to antibiotics makes new antimicrobial drugs scarcer. The
antibiotic resistome, a collection of microbial resistance genes that are widely dispersed across a variety of environmental niches and that predate the use of antibiotics by millions of years, is revealed by studies on environmental microorganisms
(D’Costa etal. 2011; Spitzer etal. 2016).
Species of Candida, Cryptococcus, Aspergillus, and Pneumocystis are implicated in nearly 90% of fungal infections resulting in human mortality (Brown etal.
2012). Intrinsic and acquired resistance to various antifungal drug classes is preva-
lent among these species. For example, echinocandins, the most recent class of
antifungal drugs, are ineffective against Cryptococcus species in treating cryptococcal meningitis, necessitating the use of drugs developed in the 1950s despite host
toxicity issues (Morris and Lim-Wilby 2008; Day etal. 2013). The widespread use
of azole antifungals for both prevention and therapy has led to a surge in uconazole-resistant Candida infections, reaching 3400 cases per year in the United States
alone. Consequently, the Centers for Disease Control and Prevention has designated
uconazole-resistant Candida as a serious threat, on par with the threat level of
Asmethicillin-resistant Salmonella aureus. Treating invasive fungal infections is
limited to three structurally different classes of compounds, a stark contrast to the
numerous classes available for antiretroviral and antibacterial drugs (Roemer and
Krysan 2014). This limitation is primarily attributed to the close evolutionary relationship between humans and fungi, resulting in a reduced number of distinct fungal
cellular targets for drug development.

446
N. K. Borah et al.
The current arsenal of antifungal medications comprises four main classes: polyenes, azoles, echinocandins, and ucytosine. One of these classes, polyenes, operates by causing the breakdown of the fungal cell membrane when amphotericin B
(AmB) binds to ergosterol (Wiederhold 2018). This interaction leads to the leakage
of intracellular compounds, ultimately resulting in the death of the fungal cell. AmB
demonstrates broad fungicidal activity against yeasts, molds, and dimorphic fungi.
However, its clinical use is hampered by acute infusion-related toxicity, doselimiting acute and chronic nephrotoxicity, and its interaction with human cholesterolcontaining membranes. Despite efforts to improve the toxicity and tolerability
proles through different lipid-based formulations of AmB, such as liposomal AmB
and AmB lipid complex, nephrotoxic side effects and related electrolyte disturbances persist, albeit to a lesser extent (Perfect 2017).
A more signicant global threat to human health has emerged from pathogenic
fungus in recent decades. Fungi are mostly opportunistic organisms that feed on
hosts weakened by HIV infection or by modern medical interventions, such as chemotherapy and organ transplantation. They are the cause of a wide range of illnesses, from invasive infections that kill 1.5million people annually to supercial
infections that impact 1.7billion people globally (Sliwoski et al. 2013; Brown etal.
2012). Notably, a dearth of reporting guidelines for fungal diseases and issues with
misdiagnosis has resulted in unacceptably low epidemiological data for fungal
infections. Therefore, estimates of the contribution of fungal pathogens to human
morbidity and mortality are probably even higher than they already are. 90% of
cases of fungal infections that result in human mortality are thought to be caused by
species of Candida, Cryptococcus, Aspergillus, and Pneumocystis. All of these species share issues with intrinsic and acquired resistance to various antifungal drug
classes (Hashimoto and Czysz 2016; Martens and Demain 2017).
In the 1980s, a new class of antifungals, known as azoles, was introduced as
synthetic compounds. These agents disrupt the biosynthesis of ergosterol by inhibiting the cytochrome P-450-dependent enzyme lanosterol 14-α-demethylase (Shapiro
etal. 2011). By accumulating toxic ergosterol precursors and depleting ergosterol,
they subject the fungal cell to extreme membrane stress, hindering its ability to
grow. Azoles with two nitrogen atoms in the azole ring are termed imidazoles, while
those with three are called triazoles (Pandiyan and Wang 2022; Martens and Demain
2017). Among the triazoles, uconazole, itraconazole, voriconazole, and posacon-
azole are approved medications for systemic infections due to their favorable pharmacokinetic and safety proles. Imidazoles, on the other hand, are typically
employed for treating supercial infections (Xu et al. 2023). Their minimal toxicity
makes them a preferred choice for preventive measures in high-risk patients and the
primary therapy for many fungal infections in clinical settings. Unfortunately, the
widespread use of azoles has led to common instances of azole resistance, especially in Candida species (Perfect etal. 2010; Walsh etal. 2008).
Discovered in the 1950s, polyenes are broad-spectrum antifungal agents derived
from natural products. Initially, it was believed that their amphipathic properties

18 A Comprehensive and Intricate Dynamics of Aspergillus: Implications…
447
allowed direct interaction with the lipid ergosterol in membranes, leading to pore
formation, membrane permeabilization, cell leakage, and eventual cell death
(Ostrosky-Zeichner etal. 2010). However, recent investigations into structure–activity relationships have revealed that polyenes actually form large extra- membranous
aggregates, extracting vital membrane–lipid ergosterol from the plasma membrane.
These challenges the previously held notion that channel formation is the primary
mechanism of cell death (Amoretti etal. 2002; Perfect etal. 2010). The multifactorial nature of cell death is likely inuenced by ergosterol’s central role in various
crucial cellular processes. In clinical settings, polyenes can cause major side effects
such as systemic toxicity and nephrotoxicity due to structural similarities between
ergosterol and the functional mammalian analog cholesterol in humans (Bencúrová
et al. 2018; Duarte et al. 2019). To address these concerns, several lipid formulations
of amphotericin B with enhanced safety proles have been developed and are extensively used to treat invasive and disseminated mycoses, which pose a serious threat
to human life. Notably, adverse reactions to polyenes remain rare, even after years of
use in the medical eld (Vincent etal. 2013).
Introduced to the market in 2001, echinocandins represent the most recent class
of antifungals to be utilized in clinical settings. These large semi-synthetic lipopeptides disrupt cell wall integrity, leading to fungal cell death by inhibiting the cell
wall enzyme complex beta-1,3--glucan synthase (Denning 2003). Currently, the
three available echinocandin medications are caspofungin, anidulafungin, and
micafungin. Despite being well-tolerated with minimal to no side effects and exhibiting poor oral absorption, echinocandins are entirely ineffective against
Cryptococcus or Fusarium species. There is a growing concern about echinocandinresistant infections, with reports of resistance emerging in both clinical and laboratory settings (Macarron et al. 2011; Arendrup and Perlin 2014).
Fungal pathogen drug resistance is becoming a more signicant threat to global health
systems and public health across the globe. These multidrug-resistant fungal pathogens are no longer amenable to traditional antifungal medications, which makes the
creation of new antifungals essential for public health. Antifungal medications work
by taking advantage of differences in two key areas—the fungal cell wall and the cell
membrane—between human and fungal cells. Antifungals belonging to three main
classes are commonly prescribed: azoles, echinocandins, and polyenes. Amphotericin
B and other polyenes pierce the fungal cell membrane, which causes cell death (Saikia
and Bordoloi 2019). By blocking the enzyme C14-α sterol demethylase, uconazole
and other azoles cause damage to the fungal cell membrane’s structural integrity.
Capsofungin and other echinocandins hinder the formation of fungal cell walls by
blocking the synthesis of β-1,3--glucan (Swinney and Anthony 2011).
The emergence of drug resistance is the main issue facing antifungals. C. auris
drug resistance is a relevant illustration of this issue. 93% of C. auris isolates examined in a 2017 study showed resistance to the azole uconazole (Lockhart etal.

448
N. K. Borah et al.
2016). Antifungals are being used widely, which is making fungal pathogens more
resistant. An essential example of this phenomenon can be observed in azoles. Since
the 1960s, azoles have been widely used in agriculture due to their broad-spectrum
activity and low cost (Dunne etal. 2017). One way that fungal pathogens can
become resistant is by being exposed to the environment while being used in agriculture. The ability of researchers to successfully cultivate isolates of triazoleresistant A. fumigatus from tulip bulbs shipped from the Netherlands illustrates the
global spread of antifungal resistance mechanisms (Marquez and Quave 2020).
Working with A. niger presents a primary challenge in the precise manipulation of
its genome, despite its genetic tractability. The stability of engineered strains is
crucial for research purposes, necessitating a focus on rening genetic modication
techniques to enhance their reliability and efciency in future endeavors A. niger is
renowned for its capability to produce valuable secondary metabolites with diverse
applications in biotechnological processes. Nevertheless, the ongoing challenge lies
in optimizing and enhancing the yield of these compounds to fully exploit their
potential. The development of antifungal drugs using computational techniques for
human use requires meticulous safety assurance. Rigorous invitro and invivo testing is indispensable to validate the safety and efcacy of these drug candidates,
addressing both regulatory concerns and ethical considerations in the process. Given
A. niger’s adaptability across various global environments, promoting international
collaboration and data-sharing emerges as a strategic approach to overcome challenges and expedite progress in the eld. Such collaboration is instrumental in
developing innovative solutions, ensuring the comprehensive utilization of A. niger’s
potential in both scientic and industrial applications.
Addrizzo-Harris DJ, Harkin TJ, McGuinness G, Naidich DP, Rom WN (1997) Pulmonary asper-
gilloma and AIDS. A comparison of HIV-infected and HIV-negative individuals. Chest
111:612–618. https://doi.org/10.1378/chest.111.3.612
Agarwal R (2009) Allergic bronchopulmonary aspergillosis. Chest 135:805–826. https://doi.
org/10.1378/chest.08- 2586
Agarwal R, Nath A, Aggarwal AN, Gupta D, Chakrabarti A (2010) Aspergillus hypersensi-
tivity and allergic bronchopulmonary aspergillosis in patients with acute severe asthma
in a respiratory intensive care unit in North India. Mycoses 53(2):138–143. https://doi.
org/10.1111/j.1439- 0507.2008.01680.x
Agarwal R, Chakrabarti A, Shah A, Gupta D, Meis JF, Guleria R, Moss R, Denning DW (2013)
Allergic bronchopulmonary aspergillosis: review of literature and proposal of new diagnostic
and classication criteria. Clin Exp Allergy 43:850–873. https://doi.org/10.1111/cea.12141
Agarwal R, Sehgal IS, Dhooria S, Aggarwal AN (2016) Developments in the diagnosis and treat-
ment of allergic bronchopulmonary aspergillosis. Expert Rev Respir Med 10:1317–1334.
https://doi.org/10.1080/17476348.2016.1249853

18 A Comprehensive and Intricate Dynamics of Aspergillus: Implications…
Alazi E, Knetsch T, Di Falco M, Reid ID, Arentshorst M, Visser J et al (2018) Inducerindependent
production of pectinases in aspergillus Niger by overexpression of the D-galacturonic acid-
responsive transcription factor gaaR.Appl Microbiol Biotechnol 102:2723–2736
Al-Ghazali NA, Hameed ZL, Abu-Duka AB (2023) First report of aspergillus leaf spot on loquat
(Eriobotrya japonica) caused by Aspergillus fumigatus in Iraq. IOP Conf Ser Earth Environ Sci
1158(4):042030. https://doi.org/10.1088/1755- 1315/1158/4/042030
Alonso S, Ramos J, Salavert Lletí M, Pemán J (2006) Epidemiology of invasive fungal infec-
tions due to Aspergillus spp. and Zygomycetes. Clin Microbiol Infect 12:2–6. https://doi.
org/10.1111/j.1469- 0691.2006.01602.x
Amchentsev A, Kurugundla N, Saleh AG (2008) Aspergillus-related lung disease. Respir Med
1:205–215. https://doi.org/10.1016/j.rmedc.2008.08.008
Amoretti M, Amsler C, Bonomi G, Bouchta A, Bowe P, Carraro C, Cesar CL, Charlton M, Collier
MJ, Doser M, Filippini V, Fine KS, Fontana A, Fujiwara MC, Funakoshi R, Genova P, Hangst
JS, Hayano RS, Holzscheiter MH etal (2002) Production and detection of cold antihydrogen
atoms. Nature 419:456–459. https://doi.org/10.1038/nature01096
Arendrup MC, Perlin DS (2014) Echinocandin resistance. Curr Opin Infect Dis 27:484–492.
https://doi.org/10.1097/qco.0000000000000111
Aspergillus niger—bugwoodwiki (2014). Bugwood.org. https://wiki.bugwood.org/
Aspergillus_niger
Bacon CW, Glenn AE, Yates IE (2008) Fusarium verticillioides: managing the endophytic associa-
tion with maize for reduced fumonisins accumulation. Toxin Rev 27(3–4):411–446
Bassetti M, Mikulska M, Repetto E, Bernardini C, Soro O, Pia MM, Mussap M, Pallavicini FMB,
Viscoli C (2010) Invasive pulmonary aspergillosis in intensive care units: is it a real problem?
J Hosp Infect 74:186–187. https://doi.org/10.1016/j.jhin.2009.07.003
Bayram Ö, Feussner K, Dumkow M, Herrfurth C, Feussner I, Braus GH (2016) Changes of global
gene expression and secondary metabolite accumulation during light-dependent aspergillus
nidulans development. Fungal Genet Biol 87:30–53
Behera BC (2020) Citric acid from Aspergillus niger: a comprehensive overview. Crit Rev
Microbiol 46:727–749. https://doi.org/10.1080/1040841x.2020.1828815
Beijers RJ, Gosker HR, Sanders KJ, de Theije C, Kelders M, Clarke G, Cryan JF, van den Borst B,
Schols AM (2020) Resveratrol and metabolic health in COPD: a proof-of-concept randomized
controlled trial. Clin Nutr 39:2989–2997. https://doi.org/10.1016/j.clnu.2020.01.002
Ben-Ami R, Lewis RE, Kontoyiannis DP (2010) Enemy of the (immunosuppressed) state: an
update on the pathogenesis of aspergillus fumigatus infection. Br J Haematol 150:406. https://
doi.org/10.1111/j.1365- 2141.2010.08283.x
Bencúrová E, Gupta S, Sarukhanyan E, Dandekar T (2018) Identication of antifungal targets
based on computer modeling. J Fungi 4:81–81. https://doi.org/10.3390/jof4030081
Benguenab A, Chibani A (2021) Biodegradation of petroleum hydrocarbons by lamentous fungi
(Aspergillus ustus and Purpureocillium lilacinum) isolated from used engine oil contaminated
soil. Acta Ecol Sin 41(5):416–423. https://doi.org/10.1016/j.chnaes.2020.10.008
Bennett JW, Klich M (2003) Mycotoxins. Clin Microbiol Rev 16:497–516. https://doi.org/10.1128/
cmr.16.3.497- 516.2003
Bilgi M, Ugraskan V, Isik B (2023) Biosorption studies of methylene blue dye using NaOH-treated
Aspergillus niger-lled sodium alginate microbeads. Chem Eng Commun 210(9):1405–1419.
https://doi.org/10.1080/00986445.2022.2103685
Bonugli-Santos RC, dos Santos Vasconcelos MR, Passarini MR, Vieira GA, Lopes VC, Mainardi
PH et al (2015) Marine-derived fungi: diversity of enzymes and biotechnological applications.
Front Microbiol 6:269
Bösch Y, Britt E, Perren S, Naef A, Frey JE, Bühlmann A (2021) Dynamics of the apple fruit
microbiome after harvest and implications for fruit quality. Microorganisms 9(2):272
Brakhage A (2005) Systemic fungal infections caused by Aspergillus species: epidemiology,
infection process and virulence determinants. Curr Drug Targets 6(8):875–886. https://doi.
org/10.2174/138945005774912717
Brown GD, Denning DW, Gow NA, Levitz SM, Netea MG, White TC (2012) Hidden killers: human
fungal infections. Sci Transl Med 4:165rv13. https://doi.org/10.1126/scitranslmed.3004404
449

450
Cairns TC, Nai C, Meyer V (2018) How a fungus shapes biotechnology: 100 years of Aspergillus
niger research. Fungal Biol Biotechnol 5:13. https://doi.org/10.1186/s40694- 018- 0054- 5
Chandrasekar PH (2005) Antifungal resistance in Aspergillus. Med Mycol 43:295–298. https://doi.
org/10.1080/13693780400029130
Cornely OA, Maertens J, Bresnik M, Ebrahimi R, Ullmann AJ, Bouza E, Heussel CP, Lortholary
O, Rieger C, Boehme A, Aoun M, Horst H-A, Thiebaut A, Ruhnke M, Reichert D, Vianelli
N, Krause SW, Olavarria E, Herbrecht R, Trial A (2007) Liposomal amphotericin B as ini-
tial therapy for invasive mold infection: a randomized trial comparing a high-loading dose
regimen with standard dosing (AmBiLoad trial). Clin Infect Dis 44:1289–1297. https://doi.
org/10.1086/514341
Cullinan P, Brown R, Field A, Hourihane J, Jones M, Kekwick R, Rycroft R, Stenz R,
Williams S, Woodhouse C (2003) Latex allergy. A position paper of the british soci-
ety of allergy and clinical immunology. Clin Exp Allergy 33:1484–1499. https://doi.
org/10.1046/j.1365- 2222.2003.01818.x
D’Costa VM, King CE, Kalan L, Morar M, Sung WW, Schwarz C, Froese D, Zazula G, Calmels
F, Debruyne R, Golding GB, Poinar HN, Wright GD (2011) Antibiotic resistance is ancient.
Nature 477:457–461. https://doi.org/10.1038/nature10388
Dagenais TR, Keller NP (2009) Pathogenesis of Aspergillus fumigatus in invasive Aspergillosis.
Clin Microbiol Rev 22:447–465. https://doi.org/10.1128/cmr.00055- 08
Dannaoui E (2001) Acquired itraconazole resistance in Aspergillus fumigatus. J Antimicrob
Chemother 47:333–340. https://doi.org/10.1093/jac/47.3.333
Day JN, Chau TTH, Wolbers M, Mai PP, Dung NT, Mai NH, Phu NH, Nghia HD, Phong ND, Thai
CQ, Thai LH, Chuong LV, Sinh DX, Duong VA, Hoang TN, Diep PT, Campbell JI, Sieu TPM,
Baker SG, Chau NVV (2013) Combination antifungal therapy for cryptococcal meningitis. N
Engl J Med 368:1291–1302. https://doi.org/10.1056/nejmoa1110404
de Moura Dickel JD, Carvalho JK, MAD S, Menegotto Dos Santos P, MLF R, Fagundes-Klen MR,
Rosa CA, Johann S, Buzanello CV, da Silva de Lucca RA, de Oliveira Santos AR, da Rosa
MF (2022) Aspergillus sclerotiorum lipolytic activity and its application in bioremediation of
high- fat dairy wastewater environments. Environ Sci Pollut Res 30(13):35517–35527. https://
doi.org/10.1007/s11356- 022- 24669- z
Denning DW (2003) Echinocandin antifungal drugs. Lancet 362:1142–1151. https://doi.
org/10.1016/s0140- 6736(03)14472- 8
Denning DW, Lee JY, Hostetler JS, Pappas P, Kauffman CA, Dewsnup DH, Galgiani JN,
Graybill JR, Sugar AM, Catanzaro A (1994) NIAID mycoses study group multicenter trial
of oral itraconazole therapy for invasive aspergillosis. Am J Med 97:135–144. https://doi.
org/10.1016/0002- 9343(94)90023- x
Denning DW, Pleuvry A, Cole DC (2012) Global burden of chronic pulmonary aspergillosis com-
plicating sarcoidosis. Eur Respir J 41:621–626. https://doi.org/10.1183/09031936.00226911
Dos Reis TF, MAC H, Colabardini AC, Fernandes CM, Silva LP, Bastos RW, MVL F, Wang F,
Martins C, Rodrigues ML, Silva Pereira C, Del Poeta M, Wong KH, Goldman GH (2021)
Screening of chemical libraries for new antifungal drugs against Aspergillus fumigatus reveals
sphingolipids are involved in the mechanism of action of miltefosine. MBio 12:e0145821.
https://doi.org/10.1128/mbio.01458- 21
Duarte Y, Márquez-Miranda V, Miossec MJ, González-Nilo F (2019) Integration of target discov-
ery, drug discovery and drug delivery: a review on computational strategies. WIREs Nanomed
Nanobiotechnol 11:e1554. https://doi.org/10.1002/wnan.1554
Dunne K, Hagen F, Pomeroy N, Meis JF, Rogers TR (2017) Intercountry transfer of triazole-
resistant Aspergillus fumigatus on plant bulbs. Clin Infect Dis 65:147–149. https://doi.
org/10.1093/cid/cix257
Farazuddin M, Mishra R, Jing Y, Srivastava V, Comstock AT, Sajjan US (2018) Quercetin prevents
rhinovirus-induced progression of lung disease in mice with COPD phenotype. PLoS One
13:e0199612. https://doi.org/10.1371/journal.pone.0199612
Fernández-Rodríguez A, Burton JL, Andreoletti L, Alberola J, Fornes P, Merino I, Martínez
MJ, Castillo P, Sampaio-Maia B, Caldas IM, Saegeman V, Cohen MC (2019) Post-mortem
N. K. Borah et al.

18 A Comprehensive and Intricate Dynamics of Aspergillus: Implications…
microbiology in sudden death: sampling protocols proposed in different clinical settings. Clin
Microbiol Infect 25:570–579. https://doi.org/10.1016/j.cmi.2018.08.009
Ferrari M, Bodini I, Cascio VL (2004) Rhabdomyolysis after the administration of itraconazole
to an asthmatic patient with bronchopulmonary aspergillosis. Respiration 71:289. https://doi.
org/10.1159/000077429
Fournier EC (1987) Trial of ketoconazole in allergic bronchopulmonary aspergillosis. Thorax
42:831. https://doi.org/10.1136/thx.42.10.831
Gamalathge DR, Perera SDHS (2023) Allergic bronchopulmonary aspergillosis in a patient with
poorly controlled bronchial asthma. Cureus 15:e46666. https://doi.org/10.7759/cureus.46666
Gloria C, Osarolai J (2023) Black hard rot disease of Cola nitida and its fungal associates. Asian J
Plant Pathol 17(1):1–6. https://doi.org/10.17311/ajpp.2023.01.06
Groll A, Shah P, Mentzel C, Schneider M, Justnuebling G, Huebner K (1996) Trends in the post-
mortem epidemiology of invasive fungal infections at a University Hospital. J Infect 33:23–32.
https://doi.org/10.1016/s0163- 4453(96)92700- 0
Gupta P, Ravi I, Sharma V (2013) Induction of β-1, 3-glucanase and chitinase activity in the
defense response of Eruca sativa plants against the fungal pathogen Alternaria brassicicola. J
Plant Interact 8(2):155–161
Gupta R, Rai CS (2020) Identication of novel drug targets in pathogenic Aspergillus fumigatus:
an in silico approach. In: Data science and analytics. Springer EBooks, Berlin, pp151–160.
https://doi.org/10.1007/978- 981- 15- 5827- 6_13
Hashimoto M, Czysz K (2016) Translational prospects and challenges in human induced pluripo-
tent stem cell research in drug discovery. Cells 5:46–46. https://doi.org/10.3390/cells5040046
Helmi S, Khalil AI, Tahoun MK, Khairy AH (1991) Induction of mutation in aspergillus Niger for
conversion of cellulose into glucose. Appl Biochem Biotechnol 28:203–210
Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann J-W, Kern WV, Marr
KA, Ribaud P, Lortholary O, Sylvester R, Rubin RH, Wingard JR, Stark P, Durand C, Caillot
D, Thiel E, Chandrasekar PH, Hodges MR, Schlamm HT (2002) Voriconazole versus ampho-
tericin b for primary therapy of invasive aspergillosis. N Engl J Med 347:408–415. https://doi.
org/10.1056/nejmoa020191
Hinson KF, Moon AJ, Plummer NS (1952) Broncho-pulmonary aspergillosis: a review and a report
of eight new cases. Thorax 7:317–333. https://doi.org/10.1136/thx.7.4.317
Huan T, Wu X, Chen JY (2023) Systems biology visualization tools for drug target discovery.
Expert Opin Drug Discovery 5:425. https://doi.org/10.1517/17460441003725102
Huang X, Men P, Tang S, Lu X (2021) Aspergillus terreus as an industrial lamentous fungus for
pharmaceutical biotechnology. Curr Opin Biotechnol 69:273–280. https://doi.org/10.1016/j.
copbio.2021.02.004
Hyeon H, Min CW, Moon K, Cha J, Gupta R, Park SU, Kim ST, Kim JK (2020) Metabolic
proling- based evaluation of the fermentative behavior of Aspergillus oryzae and Bacillus sub-
tilis for soybean residues treated at different temperatures. Food Secur 9(2):117–117. https://
doi.org/10.3390/foods9020117
Iyalla C (2015) Spectrum of aspergillosis: pathogenesis, risk factors and management. Afr J Clin
Exp Microbiol 17:35. https://doi.org/10.4314/ajcem.v17i1.5
Kosmidis C, Denning WD (2014) The clinical spectrum of pulmonary aspergillosis. Thorax
70:270–277. https://doi.org/10.1136/thoraxjnl- 2014- 206291
Kritsi E, Matsoukas M-T, Potamitis C, Detsi A, Ivanov M, Soković M, Zoumpoulakis P (2019)
Novel hit compounds as putative antifungals: the case of Aspergillus fumigatus. Molecules
24:3853–3853. https://doi.org/10.3390/molecules24213853
Kumar AK, Parikh BS (2015) Cellulose-degrading enzymes from aspergillus terreus D34 and
enzymatic saccharication of mild-alkali and dilute-acid pretreated lignocellulosic biomass
residues. Bioresour Bioprocess 2:1–13
Kume H, Yamazaki T, Abe M, Tanuma H, Okudaira M, Okayasu I (2006) Epidemiology of vis-
ceral mycoses in patients with leukemia and MDS-analysis of the data in annual of patho-
logical autopsy cases in Japan in 1989, 1993, 1997 and 2001. Nippon Ishinkin Gakkai Zasshi
47:15–24. https://doi.org/10.3314/jjmm.47.15
451

452
Kumar R, Singh P, Dhir B, Sharma AK, Mehta D (2014) Potential of some fungal and bacte-
rial species in bioremediation of heavy metals. Journal of Nuclear Physics, Material Sciences,
Radiation and Applications 1(2):213–223
Lambou K, Tag A, Lassagne A, Collemare J, Clergeot PH, Barbisan C et al (2024) The bZIP tran-
scription factor BIP1 of the rice blast fungus is essential for infection and regulates a specic
set of appressorium genes. PLoS Pathog 20(1):e1011945
Lee Y, Robbins N, Cowen LE (2023) Molecular mechanisms governing antifungal drug resistance.
NPJ Antimicrob Resist 1:5. https://doi.org/10.1038/s44259- 023- 00007- 2
Liu M (2021) Application of Aspergillus niger in the resourcable utilization of straw. IOP Conf Ser
859:012092–012092. https://doi.org/10.1088/1755- 1315/859/1/012092
Lockhart SR, Etienne KA, Vallabhaneni S, Farooqi J, Chowdhary A, Govender NP, Colombo AL,
Calvo B, Cuomo CA, Desjardins CA, Berkow EL, Castanheira M, Magobo RE, Jabeen K,
Asghar RJ, Meis JF, Jackson B, Chiller T, Litvintseva AP (2016) Simultaneous emergence of
multidrug-resistant Candida auris on 3 continents conrmed by whole-genome sequencing
and epidemiological analyses. Clin Infect Dis 64:134–140. https://doi.org/10.1093/cid/ciw691
Macarron R, Banks MN, Bojanic D, Burns DJ, Cirovic DA, Garyantes T, Green DV, Hertzberg RP,
Janzen WP, Paslay JW, Schopfer U, Sittampalam GS (2011) Impact of high-throughput screen-
ing in biomedical research. Nat Rev Drug Discov 10:188–195. https://doi.org/10.1038/nrd3368
Mackel JJ, Steele C (2019) Host defense mechanisms against aspergillus fumigatus lung coloniza-
tion and invasion. Curr Opin Microbiol 52:14–19. https://doi.org/10.1016/j.mib.2019.04.003
Mandeel QA (2005) Fungal contamination of some imported spices. Mycopathologia 159:291–298
Margalit A, Kavanagh K (2015) The innate immune response to Aspergillus fumigatus at the alveo-
lar surface. FEMS Microbiol Rev 39:670–687. https://doi.org/10.1093/femsre/fuv018
Marquez L, Quave CL (2020) Prevalence and therapeutic challenges of fungal drug resistance:
role for plants in drug discovery. Antibiotics 9:150. https://doi.org/10.3390/antibiotics9040150
Martens E, Demain AL (2017) The antibiotic resistance crisis, with a focus on the United States. J
Antibiot 70:520–526. https://doi.org/10.1038/ja.2017.30
Mattos R, Franco DG, Chaves PO, Giannesi GC, Masui DC, Ruller R, Corrêa BO, Brasil S,
Zanoelo FF (2021) Plant growth promoting potential of endophytic Aspergillus niger 9-p
isolated from native forage grass in Pantanal of Nhecolândia region, Brazil. Rhizosphere
18:100332–100332. https://doi.org/10.1016/j.rhisph.2021.100332
Maurya V, Gugnani HC, Sarma PU, Madan T, Shah A (2005) Sensitization to aspergillus anti-
gens and occurrence of allergic bronchopulmonary aspergillosis in patients with asthma. Chest
127:1252–1259. https://doi.org/10.1016/s0012- 3692(15)34474- 3
Moghaddam SJ, Barta P, Mirabolfathinejad SG, Ammar-Aouchiche Z, Garza N, Thi T, Newman
RA, Aggarwal BB, Evans CM, Tuvim MJ, Lotan R, Dickey BF (2009) Curcumin inhib-
its COPD-like airway inammation and lung cancer progression in mice. Carcinogenesis
30:1949–1956. https://doi.org/10.1093/carcin/bgp229
Money NP (2016) Fungi and biotechnology. In: The fungi. Elsevier EBooks, Amsterdam,
pp401–424. https://doi.org/10.1016/b978- 0- 12- 382034- 1.00012- 8
Monod M, Capoccia S, Léchenne B, Zaugg C, Holdom MD, Jousson O (2002) Secreted proteases from
pathogenic fungi. Int J Med Microbiol 292:405–419. https://doi.org/10.1078/1438- 4221- 00223
Moritomo A, Yamada H, Watanabe T, Itahana H, Akuzawa S, Okada M, Ohta M (2013) Synthesis
and structure–activity relationships of new carbonyl guanidine derivatives as novel dual
5-HT2B and 5-HT7 receptor antagonists. Bioorg Med Chem 21:7841–7852. https://doi.
org/10.1016/j.bmc.2013.10.010
Morris GM, Lim-Wilby MSL (2008) Molecular docking. Methods Mol Biol 443:365–382. https://
doi.org/10.1007/978- 1- 59745- 177- 2_19
Nathan SD, Shorr AF, Schmidt M, Burton NA (2000) Aspergillus and endobronchial abnormali-
ties in lung transplant recipients. Chest 118:403–407. https://doi.org/10.1378/chest.118.2.403
Nayak S, Samanta S, Mukherjee AK (2020) Benecial role of Aspergillus sp. in agricul-
tural soil and environment. CRC Press EBooks, London, pp 17–36. https://doi.org/10.120
1/9780429485794- 3
N. K. Borah et al.

18 A Comprehensive and Intricate Dynamics of Aspergillus: Implications…
News-Medical (2018) What is Aspergillus niger? News-Medicalnet. https://www.news- medical.
net/life- sciences/What- is- Aspergillus- niger.aspx#:~:text=Some%20strains%20of%20
Aspergillus%20niger,human%20health%20through%20their%20consumption
Oishi T, Ouchi K (2022) Recent trends in the epidemiology, diagnosis, and treatment of macrolide-
resistant mycoplasma pneumoniae. J Clin Med 11:1782. https://doi.org/10.3390/jcm11071782
Ostrosky-Zeichner L, Casadevall A, Galgiani JN, Odds FC, Rex JH (2010) An insight into the
antifungal pipeline: selected new molecules and beyond. Nat Rev Drug Discov 9:719–727.
https://doi.org/10.1038/nrd3074
Otu A, Kosmidis C, Mathioudakis AG, Ibe C, Denning DW (2023) The clinical spectrum of
aspergillosis in chronic obstructive pulmonary disease. Infection 51:813–829. https://doi.
org/10.1007/s15010- 022- 01960- 2
Pagadala NS, Syed K, Tuszyński JA (2017) Software for molecular docking: a review. Biophys
Rev 9:91–102. https://doi.org/10.1007/s12551- 016- 0247- 1
Pandiyan S, Wang L (2022) A comprehensive review on recent approaches for cancer drug discov-
ery associated with articial intelligence. Comput Biol Med 150:106140–106140. https://doi.
org/10.1016/j.compbiomed.2022.106140
Paoletti M, Seymour FA, Alcocer MJ, Kaur N, Calvo AM, Archer DB, Dyer PS (2007) Mating
type and the genetic basis of self-fertility in the model fungus aspergillus nidulans. Curr Biol
17(16):1384–1389
Parker JE, Andrew P, Mullins CJ, Kelly D, Kelly SL (2014) Resistance to antifungals that target
CYP51. J Chem Biol 7:143–161. https://doi.org/10.1007/s12154- 014- 0121- 1
Parmar SJ (2002) Profound adrenal suppression secondary to treatment with low dose inhaled
steroids and itraconazole in allergic bronchopulmonary aspergillosis in cystic brosis. Thorax
57:749–750. https://doi.org/10.1136/thorax.57.8.749
Patterson R, Greenberger PA, Harris KE (2000) Allergic bronchopulmonary aspergillosis. Chest
118:7–8. https://doi.org/10.1378/chest.118.1.7
Paul S, Zhang A, Ludeña Y, Villena GK, Yu F, Sherman DH, Gutiérrez-Correa M (2017) Insights
from the genome of a high alkaline cellulase producing aspergillus fumigatus strain obtained
from Peruvian Amazon rainforest. J Biotechnol 251:53–58
Perfect JR (2017) The antifungal pipeline: a reality check. Nat Rev Drug Discov 16:603–616.
https://doi.org/10.1038/nrd.2017.46
Perfect JR, Dismukes WE, Dromer F, Goldman DL, Graybill JR, Hamill RJ, Harrison TS, Larsen
RA, Lortholary O, Nguyen M, Pappas PG, Powderly WG, Singh N, Sobel JD, Sorrell TC
(2010) Clinical practice guidelines for the management of cryptococcal disease: 2010
update by the infectious diseases society of america. Clin Infect Dis 50:291–322. https://doi.
org/10.1086/649858
Person AK, Chudgar SM, Norton BL, Tong BC, Stout JE (2010) Aspergillus niger: an unusual cause
of invasive pulmonary aspergillosis. J Med Microbiol 59:834–838. https://doi.org/10.1099/
jmm.0.018309- 0
Pfaller MA, Boyken L, Hollis RJ, Kroeger J, Messer SA, Tendolkar S, Diekema DJ (2007) In vitro
susceptibility of invasive isolates of candida spp. to anidulafungin, caspofungin, and micafun-
gin: six years of global surveillance. J Clin Microbiol 46:150–156. https://doi.org/10.1128/
jcm.01901- 07
Pierce CG, Lopez-Ribot JL (2013) Candidiasis drug discovery and development: new approaches
targeting virulence for discovering and identifying new drugs. Expert Opin Drug Discovery
8:1117–1126. https://doi.org/10.1517/17460441.2013.807245
Poulsen JS, Madsen AM, White JK, Nielsen JL (2021) Physiological responses of Aspergillus
niger challenged with itraconazole. Antimicrob Agents Chemother 65:e02549. https://doi.
org/10.1128/aac.02549- 20
Razavizadeh BM, Shahrampour D, Niazmand R (2024) Investigating the effect of acoustic waves
on spoilage fungal growth and shelf life of strawberry fruit. Fungal Biol 128:1705. https://doi.
org/10.1016/j.funbio.2024.02.002
453

454
Regnard J-F, Icard P, Nicolosi M, Spagiarri L, Magdeleinat P, Jauffret B, Levasseur P (2000)
Aspergilloma: a series of 89 surgical cases. Ann Thorac Surg 69:898–903. https://doi.
org/10.1016/s0003- 4975(99)01334- x
Roemer T, Boone C (2013) Systems-level antimicrobial drug and drug synergy discovery. Nat
Chem Biol 9:222–231. https://doi.org/10.1038/nchembio.1205
Roemer T, Krysan JD (2014) Antifungal drug development: challenges, unmet clinical needs, and
new approaches. Cold Spring Harb Perspect Med 4:a019703. https://doi.org/10.1101/cshper-
spect.a019703
Romero-Olivares AL, Meléndrez-Carballo G, Lago-Lestón A, Treseder KK (2019) Soil metatran-
scriptomes under long-term experimental warming and drying: fungi allocate resources to cell
metabolic maintenance rather than decay. Front Microbiol 10:1914
Sabino R, Gonçalves P, Melo M, Simões D, Oliveira M, Francisco M, Viegas C, Carvalho D,
Martins C, Ferreira T, Toscano C, Simões H, Veríssimo C (2021) Trends on Aspergillus epi-
demiology—perspectives from a national reference laboratory surveillance program. J Fungi
7:28. https://doi.org/10.3390/jof7010028
Saikia S, Bordoloi M (2019) Molecular docking: challenges, advances and its use in
drug discovery perspective. Curr Drug Targets 20:501–521. https://doi.org/10.217
4/1389450119666181022153016
Schäfer D, Schmitz K, Weuster-Botz D, Philipp Benz J (2020) Comparative evaluation of
Aspergillus niger strains for endogenous pectin-depolymerization capacity and suitabil-
ity for D-galacturonic acid production. Bioprocess Biosyst Eng 43:1549–1560. https://doi.
org/10.1007/s00449- 020- 02347- z
Schuster E, Dunn-Coleman N, Frisvad JC, Van Dijck PW (2002a) On the safety of aspergillus
Niger–a review. Appl Microbiol Biotechnol 59:426–435
Schwarz C, Eschenhagen PN, Mainz JG, Schmidergall T, Schuette H, Romanowska E (2024)
Pulmonary aspergillosis in people with cystic brosis. Semin Respir Crit Care Med
45(01):128–140. https://doi.org/10.1055/s- 0043- 1777267
Segal BH, Walsh TJ (2006) Current approaches to diagnosis and treatment of invasive aspergil-
losis. Am J Respir Crit Care Med 173:707–717. https://doi.org/10.1164/rccm.200505- 727so
Shah A, Panchal N, Agarwal AK (2001) Concomitant allergic bronchopulmonary aspergillosis
and allergic Aspergillus sinusitis: a review of an uncommon association*. Clin Exp Allergy
31:1896–1905. https://doi.org/10.1046/j.1365- 2222.2001.01159.x
Shahi M, Amin S, Nabili M, Aliyali M, Khodavaisy S, Badali H (2015) Aspergillus colonization
in patients with chronic obstructive pulmonary disease. Curr Med Mycol 1:45–51. https://doi.
org/10.18869/acadpub.cmm.1.3.45
Shapiro SR, Robbins N, Cowen EL (2011) Regulatory circuitry governing fungal development,
drug resistance, and disease. Microbiol Mol Biol Rev 75:213–267. https://doi.org/10.1128/
mmbr.00045- 10
Singla E, Dharwal V, Naura AS (2020) Gallic acid protects against the COPD-linked lung
inammation and emphysema in mice. Inamm Res 69:423–434. https://doi.org/10.1007/
s00011- 020- 01333- 1
Sliwoski G, Kothiwale S, Meiler J, Lowe EW (2013) Computational methods in drug discovery.
Pharmacol Rev 66:334–395. https://doi.org/10.1124/pr.112.007336
Solomon WR, Burge H, Boise J (1978) Airborne levels outside and within a large clinical center. J
Allergy Clin Immunol 62:56–60. https://doi.org/10.1016/0091- 6749(78)90073- 8
Son Y-E, Park H-S (2024) SscA is required for fungal development, aatoxin production, and
pathogenicity in Aspergillus avus. Int J Food Microbiol 413:110607–110607. https://doi.
org/10.1016/j.ijfoodmicro.2024.110607
Speth C, Rambach G (2012) Complement attack against Aspergillus and corresponding evasion
mechanisms. Interdiscip Perspect Infect Dis 2012:1–9. https://doi.org/10.1155/2012/463794
Spitzer M, Robbins N, Wright GD (2016) Combinatorial strategies for combating invasive fungal
infections. Virulence 8:169–185. https://doi.org/10.1080/21505594.2016.1196300
Stevens DA, Kan VL, Judson MA, Morrison VA, Dummer S, Denning DW, Bennett JE, Walsh TJ,
Patterson TF, Pankey GA (2000) Practice guidelines for diseases caused by Aspergillus. Clin
Infect Dis 30:696–709. https://doi.org/10.1086/313756
N. K. Borah et al.
Соседние файлы в папке Библиотека им академика М.И. Перельмана
